HK Stock Market Move | LONGBIO-B(01779) rose by over 6%, LP-003 reached the primary endpoint in phase III clinical trials for seasonal allergic rhinitis.

LONGBIO-B (01779) rose more than 6%, reaching a 6.56% increase as of the release, closing at 161 Hong Kong dollars with a trading volume of 22.9196 million Hong Kong dollars. On the news front, recently, LONGBIO-B announced that the Phase III clinical trial of LP-003 for seasonal allergic rhinitis (allergic rhinitis) has achieved the pre-determined primary endpoint, and these results are statistically and clinically highly significant. The Phase III clinical trial of LP-003 for the indication of seasonal allergic rhinitis is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study conducted in China, aiming to compare the efficacy of LP-003 with placebo in the treatment of moderate to severe seasonal allergic rhinitis that is poorly controlled by standard therapy. Sealand pointed out that LP-003 can cover multiple indications, with product approvals and/or initiation of related clinical trials for multiple indications, including seasonal AR, CSU, allergic asthma, CRSwNP, and food allergy. In addition, preliminary Phase II clinical data for LP-003 show potential surpassing that of omalizumab. According to Yimeiduo, the LP-003 200mg Q8W group showed significant superiority over omalizumab in the primary clinical endpoints "Proportion of Patients with UAS7=0 at Week 12" and change in UAS7 from baseline at week 12.